Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

396
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
396
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

313
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
313
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

4.3K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.3K
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

132
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
132
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

163
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
163
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance01:09

Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance

442
Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
442

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Using prescription drug data for timely assessments of state insurance coverage rates: a validation study.

Health affairs scholar·2026
Same author

High Cost of Cancer Medicines in the United States: Opportunities for Policy Reforms.

JCO oncology practice·2026
Same author

Orphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis.

Clinical pharmacology and therapeutics·2026
Same author

Post-Approval Pediatric Use of Drugs Granted Waivers from Pediatric Testing.

Clinical pharmacology and therapeutics·2026
Same author

Reforming Payment for Clinician-Administered Drugs - Most-Favored-Nation Pricing in Medicare Part B.

The New England journal of medicine·2026
Same author

Deeming Doesn't Deliver: Reliance on foreign regulators targets the wrong stage of Canadian drug access.

Health policy (Amsterdam, Netherlands)·2026

相关实验视频

Updated: Jan 6, 2026

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

11.9K

克洛法齐米因的奇怪限制

Maple Goh1,2,3, Daniel Eisenkraft Klein1, Aaron S Kesselheim1

  • 1Program On Regulation, Therapeutics And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, 1620 Tremont, Suite 3030, Boston, MA 02120, USA.

The Journal of antimicrobial chemotherapy
|November 19, 2025
PubMed
概括

对于麻风和其他真菌细菌感染至关重要的克洛法齐明,在美国面临着进入障碍. 需要新的政策来确保公平和可持续地获得这种必不可少的药物.

更多相关视频

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.5K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.3K

相关实验视频

Last Updated: Jan 6, 2026

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

11.9K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.5K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.3K

科学领域:

  • 药理学和公共卫生
  • 全球卫生政策 全球卫生政策

背景情况:

  • 克洛法齐明是世卫组织推的治疗多细菌性麻风的药物.
  • 它也是对耐药结核病和非结核菌感染的新兴选择.
  • 尽管几十年来安全使用,但在像美国这样的高收入国家,访问是受限制的.

研究的目的:

  • 为了检查clofazimine在美国的监管历史.
  • 为了对比clofazimine的全球访问模型.
  • 突出单一制造商依赖和捐赠计划的问题.

主要方法:

  • 对监管途径的审查.
  • 全球访问策略的比较分析.
  • 对供应链漏洞的评估.

主要成果:

  • 美国目前的制度对公平获取存在局限性.
  • 依赖于单一的制造商和非正式捐款造成了供应不稳定.
  • 现有的获取模式往往不适合低利的基本药物.

结论:

  • 政策改革是必要的,以确保可持续和公平的 clofazimine 访问.
  • 建议包括简化获取,基于世卫组织的采购和公共制造.
  • 对于具有有限商业可行性的基本药物而言,主动管理至关重要.